| Name | Okyo Pharma Limited NPV |
|---|---|
| Epic | OKYO |
| Isin | GG00BD3FV870 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1.40p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £23.22 | Debt ratio | n/a |
| Shares in issue | 1,658.79 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -202.93 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | n/a | 52-week high / low | 1.40p / 5.40p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Okyo Pharma Limited NPV |
|---|---|
| Address | Martello Court, Admiral Park, St. Peter Port, Guernsey, United Kingdom, GY1 3HB |
| Telephone | |
| Website | http://okyopharma.com/ |
| Director | Position |
|---|---|
| Mr Gary S. Jacob | CEO |
| Mr John Brancaccio | Non-Executive Director |
| Mr Bernard Denoyer | Non-Executive Director |
| Mr Gabriele Cerrone | Non-Executive Chairman |
| Mr Willy Jules Simon | Senior Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/03/22 | 31/03/21 | 31/03/20 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | n/a | 0.08 | 0.02 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.62 | 0.03 | 0.19 |
| Cash and equivalents | 2.06 | 4.99 | 0.19 |
| Other current assets and asset held for resale | 0.59 | 0.04 | 0.08 |
| Total of all assets | 3.27 | 5.14 | 0.48 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 1.03 | 1.24 | 0.57 |
| Long term liabilities | n/a | 0.05 | 0.02 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.03 | 1.28 | 0.6 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 2.24 | 3.85 | -0.11 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | n/a | n/a | n/a |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -76.85 | -72.15 | -69.42 |
| Share premium account | 77.18 | 66.71 | 67.52 |
| Total equity | 2.24 | 3.85 | -0.11 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -4.55 | -2.57 | -1.21 |
| Pre-tax profit | -4.55 | -2.58 | -1.27 |